Impact of HER2‐low expression on the efficacy of endocrine therapy with or without CDK4/6 inhibitor in HR‐positive/HER2‐negative metastatic breast cancer: A prospective study
Abstract Background CDK4/6 inhibitors in combination with traditional endocrine therapy (ET) have become the recommended first‐line therapy for HR‐positive/HER2‐negative metastatic breast cancer (MBC). The aim of this prospective study was to evaluate the relationship between HER2‐low expression and...
Guardat en:
| Autors principals: | , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Wiley
2024-04-01
|
| Col·lecció: | Thoracic Cancer |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1111/1759-7714.15282 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|